Study of the Impact of Frequency of Changing PICCline Dressings in Patients With Acute Leukemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Dressing change.
- Who it may be relevant to
- Registry conditions: Leukemia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Peripherally Inserted Central Catheters have been widely used for many years for the administration of chemotherapy to patients with cancer. However, its use entails significant infectious complications and high risks of death.The hypothesis is that increasing the rate of PICCline dressing changes will reduce the occurrence of catheter-related infections.
Detailed description
The PICCline ("Peripherally Inserted Central Catheter") is a central catheter whose brachial insertion is peripheral. It has been widely used for many years for the administration of chemotherapy to patients with cancer. Although its use is growing (2.7 million applications in the USA in 2020), significant infectious complications (especially bacteremia) and even high risks of death are generally associated with it.
In December 2013, the French Society of Hospital Hygiene (SF2H) published a guide of "Recommendations for good practices and management of risks associated with PICC" to help professionals in the use of this device. It states that the rate of dressing repair is set at a maximum of 8 days for a sterile semipermeable transparent dressing; however, this recommendation is based on a questionable level of evidence (grade E level of evidence according to the HAS). In the appendix to this guide, the analysis of the scientific literature does not highlight any articles comparing different dressing repair rates. An observational study was conducted at the University Hospital of Nîmes, in order to determine the rate of infection on PICCline in the Hematology Department. In 2019, out of the 90 PICClines applied (dressing changes every 2 days), 12 infections (local and/or systemic) were noted, i.e. 13.3%.
In order to know the current practices of the different hematology services in France, a survey was conducted to collect protocols for PICCline dressing changes. A total of 23 haematology departments were contacted, 18 of which responded. The observation was made that, although most departments respected the SF2H recommendation (15 out of 18), others proposed different rhythms of care: (a) in the Hematology department at Nîmes University Hospital, dressings are redone every 48 hours, (b) in Montpellier, the frequency was 2 to 3 times a week, (c) in Grenoble, the use of PICCline was abandoned by the medical team who noted too many infections and thromboses associated with this device, and (d) in Toulouse and Strasbourg, the PICCline was used less and less for these same reasons. Moreover, the SF2H recommendations are addressed in a general way to professionals and valid for all patients; but no study can currently affirm that they are applicable to a fragile population of immunocompromised patients in the context of intensive chemotherapy. Hematology patients have a high risk of febrile neutropenia, of around 80%, and this risk of immunosuppression is a non-negligible point in terms of infection prevention during patient management.
In 2019 in France, the Réseau de Prévention des Infections Associées aux Soins launched a campaign to monitor and prevent infections associated with invasive devices. For 3 months, data on the occurrence of infectious episodes were collected in 1001 healthcare facilities. Of the nearly 12,000 bacteremia episodes identified, 25.4% were associated with an intravascular device, 17% of which were PICCline. Moreover, the survey revealed that the highest rates of occurrence were found in the Intensive Care Unit, Oncology and Hematology departments and the prevalence of bacteremia associated with intravascular devices in Hematology represented 39.8%.
Hypothesis : increasing the rate of PICCline dressing changes will reduce the occurrence of catheter-related infections.
Interventions
- Other Dressing change
The patient circuit corresponds to that of usual care. Not part of usual patient management: * The rhythm of PICCline dressing changes, which differed between the two groups. * The collection of pain on a visual analog scale at each dressing change.
Primary outcome measures
- Rate of local and/or systemic occurrence of infection on the PICCline in controls [Time frame: Day 1+48 hours]
- Rate of local and/or systemic occurrence of infection on the PICCline in controls [Time frame: Day 9+48 hours]
- Rate of local and/or systemic occurrence of infection on the PICCline in controls [Time frame: Day 17+48 hours]
- Rate of local and/or systemic occurrence of infection on the PICCline in controls [Time frame: Day 25+48 hours]
- Rate of local and/or systemic occurrence of infection on the PICCline in controls [Time frame: Day 32+48 hours]
- Rate of local and/or systemic occurrence of infection on the PICCline in controls [Time frame: Day 39+48 hours]
- Rate of local and/or systemic occurrence of infection on the PICCline in controls [Time frame: Day 46+48 hours]
- Rate of local and/or systemic occurrence of infection on the PICCline in controls [Time frame: Day 53+48 hours]
- Rate of local and/or systemic occurrence of infection on the PICCline in controls [Time frame: Day 60+48 hours]
- Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group [Time frame: Day 1+48 hours]
Secondary outcome measures (12)
- Pain or discomfort generated by PICCline dressing changes in controls [Time frame: Day 1]
- Pain or discomfort generated by PICCline dressing changes in controls [Time frame: Day 9]
- Pain or discomfort generated by PICCline dressing changes in controls [Time frame: Day 17]
- Pain or discomfort generated by PICCline dressing changes in controls [Time frame: Day 25]
- Pain or discomfort generated by PICCline dressing changes in controls [Time frame: Day 32]
- Pain or discomfort generated by PICCline dressing changes in controls [Time frame: Day 39]
- Pain or discomfort generated by PICCline dressing changes in controls [Time frame: Day 46]
- Pain or discomfort generated by PICCline dressing changes in controls [Time frame: Day 53]
- Pain or discomfort generated by PICCline dressing changes in controls [Time frame: Day 60]
- Pain or discomfort generated by PICCline dressing changes in the experimental group [Time frame: Day 1]
- Pain or discomfort generated by PICCline dressing changes in the experimental group [Time frame: Day 3]
- Pain or discomfort generated by PICCline dressing changes in the experimental group [Time frame: Day 5]
Eligibility criteria
Inclusion criteria
- Patient with a diagnosis of acute myeloblastic leukemia.
- Patient going on intensive induction chemotherapy (causing a "high risk" situation of severe infection defined as profound neutropenia ( Polymorphonuclear neutrophil count <500/mm3) and lasting (>7 days).
- Patients who have had a PICCline placed within the last 24 hours or who require a PICCline placement as part of their hospitalization under optimal hygiene and asepsis conditions.
- Patient housed in a protected environment (flow chamber or Plasmair®).
- Patient who has given free and informed consent.
- Patient affiliated or beneficiary of a health insurance plan.
- Adult patient (≥18 years old).
Exclusion criteria
- Patient with PICCline placed during a previous hospitalization.
- Patient in an exclusion period determined by another study.
- Patient under court protection, guardianship or curatorship.
- Patient unable to give consent.
- Patient for whom it is impossible to give informed information.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
France · 1 center
- CHU de Montpellier Hôpital St-Eloi — Montpellier
Identifiers
NCT: NCT05793801 · NIMAO/2021-2/JL-01